BRITISH JOURNAL OF CANCER-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2022-09-12 Glori

审稿速度:3.0
偏重的研究方向：肿瘤
经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久

102 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2023-08-27 docL 来自上海

偏重的研究方向：分子标记物
经验分享：100天了，还没找到审稿人

37 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2020-03-16 Forgetting

对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）：
2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。
2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。
2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。
2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。
2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。

186 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2023-09-18 nenee 来自湖北省

偏重的研究方向：乳腺癌;肿瘤
经验分享：请问under consideration 两周了是怎么回事呢

33 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2021-04-29 orangefish

审稿速度:24.0
经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。
基因组学方向，测序纯生信挖掘。

2020.08 投稿
2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission
2020.12 修改后重投
2021.02 又是两个月审稿，两个审稿人，大修
2021.03 修回
2021.05 又是两个月审稿，接收，accepted in principle

第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。
但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。

160 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2022-06-23 ms3000000859573514

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤治疗
经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火

103 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2022-10-13 ms7000001682490134

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：一审小修
Stage Start Date
Revision Received 29th Aug 22
Waiting for Revision 22nd Aug 22
Decision made 22nd Aug 22
Under consideration 20th Aug 22
Under review 24th May 22
Under consideration 15th May 22
Author Approved Converted Files 15th May 22
Under submission 15th May 22
二审初步接受
Stage Start Date
Revision Received 26th Sep 22
Waiting for Revision 23rd Sep 22
Decision made 23rd Sep 22
Under consideration 22nd Sep 22
Under review 3rd Sep 22
Under consideration 29th Aug 22
Author Approved Converted Files 29th Aug 22
Under submission 29th Aug 22
三审正式接受
Stage Start Date
Decision made 29th Sep 22
Under consideration 26th Sep 22
Author Approved Converted Files 26th Sep 22
Under submission 26th Sep 22
审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。

109 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2021-06-10 godweiZ

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：食管癌
经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。

157 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2023-02-16 ms1000001023607781 来自上海

审稿速度:6.0 | 投稿命中率:25.0
偏重的研究方向：肿瘤样本测序数据分析
经验分享：Stage Start Date
Decision made 7th Jan 23
Under review 12th Sep 22
Under consideration 30th Aug 22
Author Approved Converted Files 30th Aug 22
Under submission 29th Aug 22
审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！

57 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1248515, encodeId=1d2f124851592, content=审稿速度:3.0 偏重的研究方向：肿瘤 经验分享：2022.07.21 Under review，2022.09.12号还是Under review，已经接近两个月了，不知掉还要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoAlkIjytYG8O8o9NLygo13F23UBLUbiam2DIibCXIeprMLP9CYYLTnEh4qQdw23ibjoibibYkwQtKu7ibg/132, createdBy=42f31730574, createdName=Glori, createdTime=Mon Sep 12 16:53:23 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2154793, encodeId=703a2154e934e, content=偏重的研究方向：分子标记物 经验分享：100天了，还没找到审稿人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=94441709139, createdName=docL, createdTime=Sun Aug 27 14:55:21 CST 2023, time=2023-08-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=586749, encodeId=8b64586e4973, content=对我而言，非常严格的杂志，可能是我单位的原因（小二本学校）： 2019.10.22投稿，10.23退回修改格式，10.24修改格式后投回，10.30 under review，11.21 一审意见返回，大修。 2019.12.28一审修稿后投回杂志，中间由于细节原因（写错了小鼠麻醉方式遭到剪辑拒稿，后提供证明材料几经波折，不再拒稿）。 2020.1.15重新投稿，1.20日under review，2.10日二审意见返回，小修（一个审稿人两个问题不放）。 2020.2.24二审修稿后投回杂志社，当天under review，3.12 三审意见返回，小修（还是前面那个审稿人针对一个问题仍然不放，药物溶解问题）。 2020.3.13将所用的相关药物实验删除后返稿（三审意见修稿投回），3.16日接收。本人之前发表的文章也不少，这个杂志绝对是最细细到让你抓狂的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49881626351, createdName=Forgetting, createdTime=Mon Mar 16 21:37:00 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2158253, encodeId=d70a215825312, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：请问under consideration 两周了是怎么回事呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XsHTcldMwNr9qJg8licZ3E3iblE2WGy8a0HZK7S2ia6N25wVmXiaIaLzJ1ztdiadf5mb7W1Ky9MwibEEKIhQQ9U2NYfQ/132, createdBy=64b21729881, createdName=nenee, createdTime=Mon Sep 18 09:56:48 CST 2023, time=2023-09-18, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=961481, encodeId=9fd696148154, content=审稿速度:24.0 经验分享：审稿周期非常长。这个杂志感觉审稿流程是选2~3个审稿人，一个审完再发去另一个审，审稿时间非常长。 基因组学方向，测序纯生信挖掘。 2020.08 投稿 2020.11 三个月后才拿到一轮审稿意见，三个审稿人两个接收一个拒，rejected with opportunity of resubmission 2020.12 修改后重投 2021.02 又是两个月审稿，两个审稿人，大修 2021.03 修回 2021.05 又是两个月审稿，接收，accepted in principle 第一轮投稿遇到一个及其苛刻的审稿人，问的问题非常之让人无语，且和文章内容基本无关。可能考虑到另外两个审稿人都是积极的评价，编辑给了一个可修改重投的拒稿。气不过抱着“被拒我也要怼你”的心理写了rebuttal letter和此审稿人进行激烈argue。结果编辑第二轮换了一批审稿人，幸运的是后续审稿没有太大的问题，修回后接收了。 但是就这个分数对生信挖掘类文章来说审稿周期确实挺长。。。做生信的投稿慎重考虑。。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=160, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7bc15488827, createdName=orangefish, createdTime=Thu Apr 29 11:39:04 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1228175, encodeId=486c12281e5d4, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤治疗 经验分享：综述审稿2个月小修建议5条，补了一个图。后面就接收了。但是后面付彩图钱的时候，连接总是打不开，就很恼火, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f1368213680, createdName=ms3000000859573514, createdTime=Thu Jun 23 10:09:47 CST 2022, time=2022-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2093603, encodeId=46142093603ea, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：一审小修 Stage Start Date Revision Received 29th Aug 22 Waiting for Revision 22nd Aug 22 Decision made 22nd Aug 22 Under consideration 20th Aug 22 Under review 24th May 22 Under consideration 15th May 22 Author Approved Converted Files 15th May 22 Under submission 15th May 22 二审初步接受 Stage Start Date Revision Received 26th Sep 22 Waiting for Revision 23rd Sep 22 Decision made 23rd Sep 22 Under consideration 22nd Sep 22 Under review 3rd Sep 22 Under consideration 29th Aug 22 Author Approved Converted Files 29th Aug 22 Under submission 29th Aug 22 三审正式接受 Stage Start Date Decision made 29th Sep 22 Under consideration 26th Sep 22 Author Approved Converted Files 26th Sep 22 Under submission 26th Sep 22 审稿人比较专业，基础研究，老外审稿，文章要求有一定得创新性，文章更容易接受。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52875423528, createdName=ms7000001682490134, createdTime=Thu Oct 13 14:09:16 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972453, encodeId=6c809e245366, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：食管癌 经验分享：2021年1月4日投稿，1月11日under review，3月5日一审意见返回要求补一些实验，5月11日修回，5月27日accept in principle。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=157, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a2cb5509177, createdName=godweiZ, createdTime=Thu Jun 10 11:05:10 CST 2021, time=2021-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2114906, encodeId=87502114906ca, content=审稿速度:6.0 | 投稿命中率:25.0 偏重的研究方向：肿瘤样本测序数据分析 经验分享：Stage Start Date Decision made 7th Jan 23 Under review 12th Sep 22 Under consideration 30th Aug 22 Author Approved Converted Files 30th Aug 22 Under submission 29th Aug 22 审稿4个月，最后编辑说没找到审稿人，然后直接拒了...很坑...白白浪费了4个多月的时间！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8478305607, createdName=ms1000001023607781, createdTime=Thu Feb 16 13:35:14 CST 2023, time=2023-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=962393, encodeId=26f0962393ff, content=大家投稿成功后一作会有收到邮件吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=161, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20b65452622, createdName=ms8000000124135786, createdTime=Mon May 03 02:34:53 CST 2021, time=2021-05-03, status=1, ipAttribution=)]

2021-05-03 ms8000000124135786

大家投稿成功后一作会有收到邮件吗？

161 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务